The performance and perspectives of dendritic cell vaccines modified by immune checkpoint inhibitors or stimulants

Ding, Jiage; Zheng, Yanyan; Wang, Gang; Zheng, Junnian; Chai, Dafei

doi:10.1016/j.bbcan.2022.188763

Cited by 6 publications

(5 citation statements)

References 139 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…ICI affect T cell immune function. T cells infiltrate the organ and cause an immune activation response ( 5 , 6 ), which destroys pancreatic beta cells and leads to absolute insulin deficiency, namely type 1 diabetes. Type 1 diabetes can be divided into delayed type 1 diabetes, acute type 1 diabetes, or fulminant type 1 diabetes.…”

Section: Discussionmentioning

confidence: 99%

Diabetic ketoacidosis induced by nivolumab in invasive mucinous adenocarcinoma of the lung: a case report and review of the literature

Yan¹,

Xie²,

Morán³

et al. 2022

Ann Transl Med

View full text Add to dashboard Cite

Background: Nivolumab is the first programmed cell death receptor 1 (PD-1) inhibitor approved in China. Compared with chemotherapy, nivolumab has shown advantages of good efficacy and safety in the treatment of a variety of tumors. However, due to its short time of use in China and lack of safety experience, clinical understanding of its adverse reactions has not been sufficiently elucidated. In recent years, cases of diabetic ketoacidosis caused by nivolumab have been reported in the emergency department, which has aroused our concern.Case Description: Here we present a serious case of diabetic ketoacidosis in a 69-year-old woman with invasive mucinous adenocarcinoma of the lung, which occurred following therapy with the PD-1 inhibitor nivolumab and dendritic cell/cytokine-induced killer cell (DC/CIK) immunotherapy. She presented with diabetic ketoacidosis 5 days after the second cycle of nivolumab administration. The patient presented with dry mouth symptoms, a maximum blood glucose of 511.2 mg/dL, hemoglobin A1c (HbA1c) level of 7.4%, urine ketone body value of 3+, and extracellular fluid residual alkali level of −3.8 mmol/L. Normal saline and insulin was initiated. The patient had no history of obesity or family history of diabetes. She received a single dose of 3.75 mg of dexamethasone treatment during this period of time which resulted in cough improvement, but did not explain the onset of the diabetes. She was treated with insulin, sitagliptin phosphate tablets and acarbose tablets. Diabetic ketoacidosis was considered an immune-related toxicity caused by nivolumab, and consequently, treatment with nivolumab was suspended. Patient was maintained under insulin treatment with a blood glucose levels normalization. Conclusions:The incubation period of nivolumab-induced diabetic ketoacidosis is dispersive and the clinical risk is high. Patients need life-long insulin therapy. Blood glucose and HbA1c should be monitored routinely before and during nivolumab immunotherapy to avoid the occurrence of diabetic ketoacidosis.After the occurrence of diabetic ketoacidosis, insulin should be used to actively control blood glucose and do a good job in medication education to ensure long-term compliance of patients. Nivolumab should only be initiated if the patient has a clinical benefit under stable glucose control.

show abstract

Section: Discussionmentioning

confidence: 99%

Diabetic ketoacidosis induced by nivolumab in invasive mucinous adenocarcinoma of the lung: a case report and review of the literature

Yan¹,

Xie²,

Morán³

et al. 2022

Ann Transl Med

View full text Add to dashboard Cite

show abstract

“…After taking up the tumor antigen, DCs migrate to the draining lymph nodes and present the antigens to T cells, activating the specific T cells that will recognize the tumor antigen and kill the tumor cells [ 135 ]. Recent advances in understanding tumor vaccines have led researchers to suggest that promoting the migration ability of DCs might further improve the efficacy of anti-tumor therapy [ 136 ], and in vivo imaging has been used to support these advances. For example, Kim HR et al discovered an inhibitory role for transgelin-2 in the migration and antigen presentation of DCs in a cancer model using in vivo imaging technology.…”

Section: Applications Of In Vivo Imaging In Studying Tumor Immunotherapymentioning

confidence: 99%

Applications of Intravital Imaging in Cancer Immunotherapy

Deng,

Hao,

et al. 2024

Bioengineering

View full text Add to dashboard Cite

Currently, immunotherapy is one of the most effective treatment strategies for cancer. However, the efficacy of any specific anti-tumor immunotherapy can vary based on the dynamic characteristics of immune cells, such as their rate of migration and cell-to-cell interactions. Therefore, understanding the dynamics among cells involved in the immune response can inform the optimization and improvement of existing immunotherapy strategies. In vivo imaging technologies use optical microscopy techniques to visualize the movement and behavior of cells in vivo, including cells involved in the immune response, thereby showing great potential for application in the field of cancer immunotherapy. In this review, we briefly introduce the technical aspects required for in vivo imaging, such as fluorescent protein labeling, the construction of transgenic mice, and various window chamber models. Then, we discuss the elucidation of new phenomena and mechanisms relating to tumor immunotherapy that has been made possible by the application of in vivo imaging technology. Specifically, in vivo imaging has supported the characterization of the movement of T cells during immune checkpoint inhibitor therapy and the kinetic analysis of dendritic cell migration in tumor vaccine therapy. Finally, we provide a perspective on the challenges and future research directions for the use of in vivo imaging technology in cancer immunotherapy.

show abstract

“…There is evidence that immune checkpoints hinder DC function, even resulting in the immune escape of tumors. [ 75 ] The tumor escape dilemma can be overcome by using ICBs, thereby interrupting tumor growth. [ 76 ] Recently, the application of ICBs has emerged as a critical antitumor strategy against multiple cancer types, such as melanoma, non‐small cell lung cancer, and renal‐cell carcinoma.…”

Section: Potential Components For Promoting Biomaterial‐mediated DC A...mentioning

confidence: 99%

Biomaterials Facilitating Dendritic Cell‐Mediated Cancer Immunotherapy

Dong

Zhang

et al. 2023

Advanced Science

View full text Add to dashboard Cite

Dendritic cell (DC)-based cancer immunotherapy has exhibited remarkable clinical prospects because DCs play a central role in initiating and regulating adaptive immune responses. However, the application of traditional DC-mediated immunotherapy is limited due to insufficient antigen delivery, inadequate antigen presentation, and high levels of immunosuppression. To address these challenges, engineered biomaterials have been exploited to enhance DC-mediated immunotherapeutic effects. In this review, vital principal components that can enhance DC-mediated immunotherapeutic effects are first introduced. The parameters considered in the rational design of biomaterials, including targeting modifications, size, shape, surface, and mechanical properties, which can affect biomaterial optimization of DC functions, are further summarized. Moreover, recent applications of various engineered biomaterials in the field of DC-mediated immunotherapy are reviewed, including those serve as immune component delivery platforms, remodel the tumor microenvironment, and synergistically enhance the effects of other antitumor therapies. Overall, the present review comprehensively and systematically summarizes biomaterials related to the promotion of DC functions; and specifically focuses on the recent advances in biomaterial designs for DC activation to eradicate tumors. The challenges and opportunities of treatment strategies designed to amplify DCs via the application of biomaterials are discussed with the aim of inspiring the clinical translation of future DC-mediated cancer immunotherapies.

show abstract

The performance and perspectives of dendritic cell vaccines modified by immune checkpoint inhibitors or stimulants

Cited by 6 publications

References 139 publications

Diabetic ketoacidosis induced by nivolumab in invasive mucinous adenocarcinoma of the lung: a case report and review of the literature

Diabetic ketoacidosis induced by nivolumab in invasive mucinous adenocarcinoma of the lung: a case report and review of the literature

Applications of Intravital Imaging in Cancer Immunotherapy

Biomaterials Facilitating Dendritic Cell‐Mediated Cancer Immunotherapy

Contact Info

Product

Resources

About